@article{2cce40f9ac3741ad8a78570286e36d88,
title = "Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report",
abstract = "Membranous nephropathy (MN) is an uncommon renal presentation in patients with chronic lymphocytic leukemia (CLL), and as such, there is no standard therapy for these patients. A few cases of MN in CLL have been described with varying success in MN treatment involving alkylating agents and fludarabine. Here we report the first case of MN in a patient with CLL treated with ibrutinib with complete renal response. This presentation underlines the importance of recognizing rare glomerular diseases that may occur with CLL and offers a new therapeutic avenue to the treatment of CLL-associated MN.",
keywords = "Bruton tyrosine kinase, Case report, Chronic lymphocytic leukemia, Membranous nephropathy, Paraneoplastic",
author = "Turcotte, {Anna Eve} and Glass, {William F.} and Lin, {Jamie S.} and Burger, {Jan A.}",
note = "Funding Information: J.S.L. is supported by National Institutes of Health ( K08DK119466 and L30CA274749 ). This research is also supported by the Division of Internal Medicine Immuno-Oncology Toxicity Award Program of the University of Texas MD Anderson Cancer Center (PI: J.S.L.) and the University Cancer Foundation via the Institutional Research Grant program at the University of Texas MD Anderson Cancer Center (PI: J.S.L.). The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672 . Publisher Copyright: {\textcopyright} 2023",
year = "2023",
month = jan,
doi = "10.1016/j.lrr.2023.100377",
language = "English (US)",
volume = "20",
journal = "Leukemia Research Reports",
issn = "2213-0489",
publisher = "Elsevier Ltd",
}